Nitric oxide (NO) signaling has been widely implicated in synaptic plasticity and memory formation (Schuman and Madison 1991; Bredt and Snyder 1992; Chapman et al. 1992; Bohme et al. 1993; Zhuo et al. 1994; Bernabeu et al. 1995; Arancio et al. 1996; Doyle et al. 1996; Holscher et al. 1996; Suzuki et al. 1996; Son et al. 1998; Zou et al. 1998; Ko and Kelly 1999; Lu et al. 1999). A highly soluble gas generated by the conversion of L-arginine to L-citrulline by the Ca2+-regulated enzyme nitric oxide synthase (NOS), NO is known to have a variety of effects both pre- and postsynaptically. One immediate downstream effector of NO, for example, is soluble guanylyl cyclase (sGC) (Bredt and Snyder 1992; Son et al. 1998; Denninger and Marletta 1999; Arancio et al. 2001). This enzyme directly leads to the formation of cyclic-GMP, and in turn, to the activation of the cGMP-dependent protein kinase (PKG). PKG, in turn, can have a number of effects, including targeting and mobilization of synaptic vesicles in the presynaptic cell, leading to enhanced transmitter release (Hawkins et al. 1993, 1998) and also to activation of protein kinase cascade in the postsynaptic cell, leading to activation of transcription and translation that are critical for long-term synaptic plasticity and memory formation (Lu et al. 1999; Chien et al. 2003).

While most widely studied in the hippocampus (Chapman et al. 1992; Bohme et al. 1993; Bernabeu et al. 1995, 1996, 1997; Holscher et al. 1996; Suzuki et al. 1996; Zou et al. 1998) and cerebellum (Chapman et al. 1992), recent evidence from our laboratory has suggested that NO signaling in the lateral nucleus of the amygdala (LA) is also critical to fear memory formation (Schafe et al. 2005a). In our study, neuronal NOS (nNOS) was shown to be expressed in LA neurons and in postsynaptic sites of excitatory synapses in the LA. Further, pharmacological manipulation of NO signaling in the LA using either a NOS inhibitor or a membrane-impermeable scavenger of NO impaired memory consolidation of auditory fear conditioning and LTP at auditory thalamic input synapses to the LA, in vitro (Schafe et al. 2005a). These findings suggest a role for NO signaling in Pavlovian fear conditioning and synaptic plasticity in the LA. Further, given that previous studies have failed to find effects of NOS blockade on LTP at cortical inputs to the LA (Watanabe et al. 1995), our recent findings suggest a rather specific role for NO signaling in synaptic plasticity at thalamic inputs to the LA.

The present study was aimed at further characterizing the role of the NO signaling pathway in fear memory consolidation and associated synaptic plasticity in the LA. In the first series of experiments, we examined the involvement of downstream effectors of NO signaling, including sGC and PKG, using pharmacological agents in both behavioral and in vitro electrophysiological experiments that both inhibit and promote activation of the NO-cGMP-PKG signaling pathway. In the second series of experiments, we examined whether the NO-cGMP-PKG signaling pathway might play a unique role in synaptic plasticity at thalamic input synapses to the LA. Finally, we asked whether NO signaling in the LA is critical to fear memory consolidation and synaptic plasticity in the LA. In the first series of experiments, we examined the involvement of downstream effectors of NO signaling, including sGC and PKG, using pharmacological agents in both behavioral and in vitro electrophysiological experiments that both inhibit and promote activation of the NO-cGMP-PKG signaling pathway. In the second series of experiments, we examined whether the NO-cGMP-PKG signaling pathway might play a unique role in synaptic plasticity at thalamic input synapses to the LA. Finally, we asked whether NO signaling in the LA is critical to fear memory consolidation and synaptic plasticity in the LA. In the first series of experiments, we examined the involvement of downstream effectors of NO signaling, including sGC and PKG, using pharmacological agents in both behavioral and in vitro electrophysiological experiments that both inhibit and promote activation of the NO-cGMP-PKG signaling pathway. In the second series of experiments, we examined whether the NO-cGMP-PKG signaling pathway might play a unique role in synaptic plasticity at thalamic input synapses to the LA. Finally, we asked whether NO signaling in the LA is critical to fear memory consolidation and synaptic plasticity in the LA. In the first series of experiments, we examined the involvement of downstream effectors of NO signaling, including sGC and PKG, using pharmacological agents in both behavioral and in vitro electrophysiological experiments that both inhibit and promote activation of the NO-cGMP-PKG signaling pathway. In the second series of experiments, we examined whether the NO-cGMP-PKG signaling pathway might play a unique role in synaptic plasticity at thalamic input synapses to the LA. Finally, we asked whether NO signaling in the LA is critical to fear memory consolidation and synaptic plasticity in the LA. In the first series of experiments, we examined the involvement of downstream effectors of NO signaling, including sGC and PKG, using pharmacological agents in both behavioral and in vitro electrophysiological experiments that both inhibit and promote activation of the NO-cGMP-PKG signaling pathway. In the second series of experiments, we examined whether the NO-cGMP-PKG signaling pathway might play a unique role in synaptic plasticity at thalamic input synapses to the LA. Finally, we asked whether NO signaling in the LA is critical to fear memory consolidation and synaptic plasticity in the LA. In the first series of experiments, we examined the involvement of downstream effectors of NO signaling, including sGC and PKG, using pharmacological agents in both behavioral and in vitro electrophysiological experiments that both inhibit and promote activation of the NO-cGMP-PKG signaling pathway. In the second series of experiments, we examined whether the NO-cGMP-PKG signaling pathway might play a unique role in synaptic plasticity at thalamic input synapses to the LA. Finally, we asked whether NO signaling in the LA is critical to fear memory consolidation and synaptic plasticity in the LA. In the first series of experiments, we examined the involvement of downstream effectors of NO signaling, including sGC and PKG, using pharmacological agents in both behavioral and in vitro electrophysiological experiments that both inhibit and promote activation of the NO-cGMP-PKG signaling pathway. In the second series of experiments, we examined whether the NO-cGMP-PKG signaling pathway might play a unique role in synaptic plasticity at thalamic input synapses to the LA. Finally, we asked whether NO signaling in the LA is critical to fear memory consolidation and synaptic plasticity in the LA. In the first series of experiments, we examined the involvement of downstream effectors of NO signaling, including sGC and PKG, using pharmacological agents in both behavioral and in vitro electrophysiological experiments that both inhibit and promote activation of the NO-cGMP-PKG signaling pathway. In the second series of experiments, we examined whether the NO-cGMP-PKG signaling pathway might play a unique role in synaptic plasticity at thalamic input synapses to the LA. Finally, we asked whether NO signaling in the LA is critical to fear memory consolidation and synaptic plasticity in the LA. In the first series of experiments, we examined the involvement of downstream effectors of NO signaling, including sGC and PKG, using pharmacological agents in both behavioral and in vitro electrophysiological experiments that both inhibit and promote activation of the NO-cGMP-PKG signaling pathway. In the second series of experiments, we examined whether the NO-cGMP-PKG signaling pathway might play a unique role in synaptic plasticity at thalamic input synapses to the LA. Finally, we asked whether NO signaling in the LA is critical to fear memory consolidation and synaptic plasticity in the LA. In the first series of experiments, we examined the involvement of downstream effectors of NO signaling, including sGC and PKG, using pharmacological agents in both behavioral and in vitro electrophysiological experiments that both inhibit and promote activation of the NO-cGMP-PKG signaling pathway. In the second series of experiments, we examined whether the NO-cGMP-PKG signaling pathway might play a unique role in synaptic plasticity at thalamic input synapses to the LA. Finally, we asked whether NO signaling in the
LA might promote synaptic plasticity and memory formation by activating the extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK), a signaling cascade known to play a critical role in fear memory consolidation (Atkins et al. 1998; Schafe et al. 2000).

Results

Inhibition of PKG in the lateral amygdala impairs fear memory consolidation and long-term potentiation at thalamic inputs to the LA

We have recently shown that blockade of NO signaling in the LA using the NOS inhibitor 7-Nitroindazole (7-Ni) or the membrane-impermeable NO scavenger carboxy-PTIO (c-PTIO) impairs memory consolidation and LTP at thalamic inputs to the LA (Schafe et al. 2005a). In this first series of experiments, we examined the role of downstream targets of NO signaling in memory consolidation of auditory fear conditioning and synaptic plasticity at thalamic inputs to the LA. In behavioral experiments, we gave rats intra-LA infusion of vehicle (0.5 µL 0.9% NaCl) or of different doses of the PKG inhibitor Rp-8-Br-PET-cGMPS (0.1 or 1.0 µg/side; 0.5 µL) prior to auditory fear conditioning and examined retention at 1, 3, 6, and 24 h after training. In slice electrophysiology experiments, we used a combination of field and whole-cell recordings to examine the role of PKG and sGC, its upstream regulator, in LTP at thalamo-LA synapses.

Behavioral experiments

The findings of the behavioral experiment can be observed in Figure 1. Rats infused with either dose of Rp-8-Br-PET-cGMPS exhibited intact post-shock freezing during training that did not significantly differ from vehicle-infused controls (Fig. 1B). The ANOVA for post-shock freezing scores showed only a significant effect of trial ($F_{(2,46)} = 14.91, P < 0.001$); the effect for drug ($F_{(2,46)} = 2.50$) and the drug by trial interaction ($F_{(4,46)} = 1.37$) were not significant. Similarly, Rp-8-Br-PET-cGMPS-infused rats tested for auditory fear memory 1 h following conditioning were found to have intact short-term memory (Fig. 1C). The ANOVA for fear memory at 1 h did not reveal a significant effect of drug condition ($F_{(2,23)} = 1.32$), for trial ($F_{(1,24)} = 0.04$), or for the drug by trial interaction ($F_{(4,46)} = 0.32$).

At 3 h, however, differences began to emerge in the group treated with the highest dose of the PKG inhibitor (Fig. 1D). The ANOVA for the 3-h memory test showed a significant effect of drug condition ($F_{(2,23)} = 3.46, P < 0.05$). The effect of trial ($F_{(2,46)} = 0.30$) and the drug by trial interaction ($F_{(4,46)} = 0.94$) were not significant. Similarly, at 6 h, the group infused with the highest dose of Rp-8-Br-PET-cGMPS differed significantly from both the vehicle and low-dose conditions (Fig. 1E). The ANOVA for the 6-h test revealed a significant effect for group ($F_{(2,23)} = 4.48, P < 0.03$) for trial ($F_{(4,46)} = 1.46$) and the drug by trial interaction ($F_{(4,46)} = 0.96$) were not significant. This difference became even more pronounced at 24 h after training, with the ANOVA revealing a significant effect of drug condition ($F_{(2,23)} = 5.46, P < 0.01$) and for trial ($F_{(1,24)} = 4.85, P < 0.01$). The drug by trial interaction ($F_{(4,46)} = 0.46$) was not significant. Duncan’s post-hoc t-tests revealed that the high-dose group differed significantly from the vehicle group on any trial ($P > 0.05$).

To further examine the consolidation deficit in rats infused with Rp-8-Br-PET-cGMPS, we expressed each animal’s freezing score at 24 h (LTM test) as a percentage of that during the 1 h (STM) test (Fig. 1G). The ANOVA revealed a significant difference ($F_{(2,23)} = 5.47, P < 0.02$), with Duncan’s post-hoc t-tests revealing a significant group difference between the high-dose condition and both the low-dose and vehicle conditions ($P < 0.05$).

Our initial experiments showed that infusion of the PKG inhibitor Rp-8-Br-PET-cGMPS into the LA dose-dependently impairs memory consolidation of auditory fear conditioning. The observation of intact post-shock freezing and memory during the 1-h test (Fig. 1B,C) rules out the possibility that Rp-8-Br-PET-cGMPS may have nonspecifically interfered with tone or shock processing during the training session. However, it remains possible that the memory impairment observed at 24 h (Fig. 1F) could reflect state-dependent learning or nonspecific damage to the LA that emerges slowly after infusion. To address these concerns, rats were reinfused with vehicle or their respective dose of drug the day following the 24-h test and retested for fear memory 1 h after infusion (Fig. 1H, top). Thus, these animals were tested for auditory fear memory retention under the influence of the drug. While not reaching significance ($F_{(2,23)} = 2.93, P < 0.08$), perhaps due to extinction in the vehicle group, the pattern of results was nonetheless similar to that of the 24-h test, in which the drug apparently does not impair post-shock freezing during the memory. Thus, it is unlikely that the memory impairment observed during the original 24-h test can be attributable to state-dependent learning.

To rule out the possibility that infusion of Rp-8-Br-PET-cGMPS produces delayed, yet nonspecific damage to the LA, all rats were retrained in the absence of any drug infusion –24 h after the end of the state-dependent test. One hour after training, animals were tested for retention of auditory fear memory (Fig. 1H, bottom). The findings revealed that all groups displayed robust and equivalent levels of freezing ($F_{(2,23)} = 0.207$), indicating that the LA was intact and not damaged by infusion of the drug. Collectively, these findings suggest that animals that had previously performed poorly on the memory-retention test likely did so due to impaired fear memory consolidation, and not because of nonspecific factors such as state-dependent learning or damage to the LA.

In our initial behavioral experiments, we infused rats with multiple doses of Rp-8-Br-PET-cGMPS prior to fear conditioning and tested each animal for retention of auditory fear conditioning at 1, 3, 6, and 24 h following training. Since rats in our first experiment were tested multiple times across a 24-h period, it might be argued that the memory impairments observed at 6 and 24 h reflect enhanced extinction under the influence of Rp-8-Br-PET-cGMPS rather than impaired memory consolidation. Alternatively, since in our initial experiments the drug was likely still present in the LA during the 1-h memory test, it might be argued that our “consolidation” deficit observed at 24 h instead reflects a “reconsolidation” deficit. To examine each of these possibilities, we gave a separate group of rats intra-LA infusion of vehicle (0.5 µL 0.9% NaCl) or of different doses of Rp-8-Br-PET-cGMPS (0.1 or 1.0 µg/side; 0.5 µL) prior to auditory fear conditioning and examined retention at 24 h after training without intervening memory tests (Fig. 2A). Rats infused with either dose of Rp-8-Br-PET-cGMPS exhibited intact post-shock freezing during training that did not significantly differ from vehicle-infused controls (Fig. 2B). The ANOVA for post-shock freezing scores showed only a significant effect of trial ($F_{(1,15)} = 46.46, P < 0.001$); the effect for drug ($F_{(4,60)} = 0.05$) and the drug by trial interaction ($F_{(4,60)} = 0.05$) were not significant. At 24 h, however, differences between the conditions were evident for both groups treated with the PKG inhibitor (Fig. 2C). The ANOVA for the 24-h memory test showed a significant effect of drug condition ($F_{(1,15)} = 3.75, P < 0.05$) and for trial ($F_{(4,60)} = 1.96, P < 0.05$). The drug by trial interaction ($F_{(18,150)} = 0.46$) was not significant. Duncan’s post-hoc t-tests revealed that the high-dose group
differed significantly from the vehicle group on all trials of the LTM test with the exception of trials 3, 8, and 10 ($P < 0.05$). The low-dose group, in contrast, differed from the vehicle group only on trials 2 and 4 ($P < 0.05$). Unlike in the first experiment, the high- and low-dose groups did not differ from each other on any trial ($P > 0.05$), indicating that the low dose of Rp-8-Br-PET-cGMPS was more effective at impairing fear memory in this experiment. This finding is likely due to the fact that a slightly weaker training protocol was used for this experiment (one pairing vs. three pairings). Overall, however, these findings suggest that it is unlikely that infusion of Rp-8-Br-PET-cGMPS in our previous experiments impaired memory by enhancing fear extinction. It is also unlikely that our initial findings are solely attributable to a "reconsolidation" effect. Rather, our findings are consistent with the interpretation that signaling via the NO-cGMP-PKG pathway is critical for fear memory consolidation.

Histological verification of the cannula placements for rats infused with 1.0 µg Rp-8-Br-PET-cGMPS (gray circles), 0.1 µg Rp-8-Br-PET-cGMPS (black circles), or 0.15 M NaCl vehicle (black squares). Panels adapted from Paxinos and Watson (1997). (*) $P < 0.05$ relative to vehicle and 0.1 µg Rp-8-Br-PET-cGMPS.

**Figure 1.** Inhibition of PKG in the LA impairs auditory fear memory consolidation. (A) Schematic of the behavioral protocol. Rats were given intra-LA infusion of either the vehicle or a high (1.0 µg) or low (0.1 µg) dose of Rp-8-Br-PET-cGMPS. Sixty minutes later they were trained with three tone-shock pairings, then tested for retention of auditory fear conditioning at 1, 3, 6, and 24 h following conditioning. (B) Mean ($\pm$ SEM) post-shock freezing between conditioning trials in rats given intra-LA infusions of 0.15 M NaCl (vehicle; $n = 8$), 1.0 µg Rp-8-Br-PET-cGMPS ($n = 8$), or 0.1 µg Rp-8-Br-PET-cGMPS ($n = 8$). (C) Mean ($\pm$ SEM) auditory fear memory assessed at 1 h following conditioning. (D) Mean ($\pm$ SEM) auditory fear memory assessed at 3 h following conditioning. (E) Mean ($\pm$ SEM) auditory fear memory assessed at 6 h following conditioning. (F) Mean ($\pm$ SEM) auditory fear memory assessed at 24 h following conditioning. (G) LTM expressed as a percentage of STM in each group. Each rat’s 24-h memory score is expressed as a percentage of its 1-h memory score. (H) Schematic of the state-dependency and reconditioning trials. Rats were given intra-LA infusion of their original drug dose (0.15M NaCl [vehicle; $n = 8$], 1.0 µg Rp-8-Br-PET-cGMPS [n = 8], or 0.1 µg Rp-8-Br-PET-cGMPS [n = 8]), then tested for auditory fear conditioning 1 h later. Rats were then reconditioned drug free and tested for auditory fear conditioning 1 h later. Mean ($\pm$ SEM) auditory fear memory assessed at 1 h following state-dependent test and at 1 h following reconditioning. (*) Histological verification of cannula placements for rats infused with 1.0 µg Rp-8-Br-PET-cGMPS (gray circles), 0.1 µg Rp-8-Br-PET-cGMPS (black circles), or 0.15 M NaCl vehicle (black squares). Panels adapted from Paxinos and Watson (1997). (*) $P < 0.05$ relative to vehicle and 0.1 µg Rp-8-Br-PET-cGMPS.
bath application of 1 μM Rp-8-Br-PET-cGMPS prior to delivery of a 30-Hz tetanus (Schafe et al. 2005a). In separate whole-cell experiments, we next examined the effect of delivering Rp-8-Br-PET-cGMPS (250 μM) to the cell in the patch pipette. This latter experiment allowed us to restrict the delivery of Rp-8-Br-PET-cGMPS to the postsynaptic cell to determine whether signaling via PKG might play a role in postsynaptic aspects of plasticity at thalamo-LA synapses.

For each experiment, the effects of bath application of each compound on the amplitude or slope of the evoked response was also measured for a 20–30 min period prior to LTP induction to determine whether the drugs had any effect on routine transmission at thalamo-LA synapses.

Relative to ACSF-perfused slices, Rp-8-Br-PET-cGMPS was found to inhibit LTP induced by stimulation of thalamic inputs to the LA (Fig. 3B). The control slices showed 125.28 ± 11.17% potentiation, which was significantly different from baseline $(t_{11} = 2.29, P < 0.05; \text{one-tailed})$. On the other hand, Rp-8-Br-PET-cGMPS-treated slices showed only 93.59 ± 7.88% potentiation, which was not significantly different from baseline $(t_{11} = 0.44, \text{P} > 0.05)$. A comparison of the control and inhibitor-treated slices revealed significantly higher levels of potentiation in the ACSF slices than in the PKG inhibitor-treated slices $(t_{6} = 2.24, P < 0.05)$ . Importantly, bath application of Rp-8-Br-PET-cGMPS had no effect on baseline transmission alone $(t_{11} = 0.47; \text{Fig. 3B, inset})$. We also found that inhibition of sGC impaired thalamo-LA LTP. Relative to ACSF-perfused controls, bath application of LB83583 impaired LTP (Fig. 3C). The control (ACSF-treated) slices exhibited 120.97 ± 6.23% potentiation, which was significantly different from baseline levels $(t_{12} = 3.60, P < 0.01)$, whereas inhibitor-treated slices showed only 103.13 ± 6.66% potentiation, which was not significantly different from baseline $(t_{12} = 0.60)$. Further, the control slices and the inhibitor-treated slices exhibited significantly different levels of LTP from each other $(t_{10} = 1.87, P < 0.05; \text{one-tailed})$. There was no effect, however, of bath application of LB83583 on routine transmission alone $(t_{12} = 1.44; \text{Fig. 3C, inset})$. The findings of the whole-cell experiments mirrored those of the field recordings. Results showed that bath application of Rp-8-Br-PET-cGMPS impaired LTP at thalamic inputs to the LA (Fig. 3D). The control cells showed 126.78 ± 6.48% potentiation, which was significantly higher than baseline $(t_{7} = 4.09, P < 0.01)$. In contrast, the PKG inhibitor-treated cells showed 90.28 ± 7.71% potentiation, which was not significantly different from baseline $(t_{6} = 0.82)$, but was significantly different from the ACSF-treated cells $(t_{13} = 3.65, P < 0.01)$. Also, as before, bath application of the drug alone had no effect on routine transmission $(t_{6} = 0.29; \text{Fig. 3D, inset})$. A similar picture emerged when Rp-8-Br-PET-cGMPS was dissolved in the recording pipette (Fig. 3E). The control cells showed 123.72 ± 6.85% potentiation, which was significantly higher than baseline $(t_{13} = 3.52, P < 0.01)$. In contrast, the PKG inhibitor-treated cells showed 86.93 ± 7.6% potentiation, which was not significantly different from baseline $(t_{10} = 1.84)$, but was significantly different from controls cells $(t_{10} = 2.95, P < 0.01)$. Further, resting membrane potentials (Vm) remained constant throughout the experiment in cells treated with Rp-8-Br-PET-cGMPS in the pipette. An analysis comparing Vm at the beginning (just after patching) and at the end of the experiment for each cell revealed no significant effects (Vm beginning = 60 ± 1.07%; Vm end = 61.2 ± 0.86%; $t_{4} = 1.5, P > 0.05$).

Together, these findings provide support for a role of sGC-cGMPS-PKG signaling in LTP induced through stimulation of thalamic inputs to the LA and in fear memory consolidation. These findings extend those of our previous report (Schafe et al. 2005a) and collectively provide strong evidence that the NO-cGMP-PKG

---

**Figure 2.** Inhibition of PKG in the LA impairs auditory fear memory consolidation independent of affecting fear extinction or reconsolidation. (A) Schematic of the behavioral protocol. Rats were given intra-LA infusion of either the vehicle or a high (1.0 μg) or low (0.1 μg) dose of Rp-8-Br-PET-cGMPS. Sixty minutes later they were trained with a single tone-shock pairing, then tested for retention of auditory fear conditioning 24 h later. (B) Mean (± SEM) post-shock freezing in rats given intra-LA infusions of 0.15 M NaCl (vehicle; $n = 6$), 1.0 μg Rp-8-Br-PET-cGMPS ($n = 5$), or 0.1 μg Rp-8-Br-PET-cGMPS ($n = 7$). (C) Mean (± SEM) auditory fear memory assessed at 24 h following conditioning. (D) Histological verification of cannula placements for rats infused with 1.0 μg Rp-8-Br-PET-cGMPS (gray circles), 0.1 μg Rp-8-Br-PET-cGMPS (light-gray circles), or 0.15 M NaCl vehicle (black circles). Panels adapted from Paxinos and Watson (1997).

**Slice electrophysiology**

We next examined the role of sGC-PKG signaling in synaptic plasticity at thalamic inputs to the LA using slice-recording methods (Fig. 3A). In these initial experiments, we examined this question using both field recordings and whole-cell patch clamp techniques. In our field-recording experiments, we bath applied either the PKG inhibitor Rp-8-Br-PET-cGMPS (1 μM) or the sGC inhibitor LB83583 (5 μM) to the slice prior to inducing LTP with a 100-Hz tetanus (given three times, separated by 1 min at 50% higher stimulus intensity; see Materials and Methods for details). This low concentration of Rp-8-Br-PET-cGMPS has been shown to be highly specific to PKG and to have little effect on other kinases such as PKA (Lu et al. 1999).

In our whole-cell experiments, we examined the effect of
Inhibition of NO-cGMP-PKG signaling fails to impair long-term potentiation at cortical inputs to the LA

In the previous series of experiments, we showed that inhibition of PKG, a downstream substrate of NO signaling, impairs fear memory consolidation and synaptic plasticity at thalamic input synapses to the LA. A previous study, however, failed to find effects of inhibition of NO signaling on amygdala LTP induced at cortical inputs (Watanabe et al. 1995). This pattern of findings raises the intriguing possibility that LTP at thalamic and cortical inputs to the LA might be characterized by distinct biochemical mechanisms. To further evaluate this possibility, we next examined the effect of inhibition of NO-cGMP-PKG signaling on LTP at cortical inputs to the LA (Fig. 4A). Given that we have not previously studied LTP at cortical-LA synapses, we began by asking whether our 100-Hz LTP induction protocol induces LTP at cortical-LA inputs that is sensitive to NMDAR blockade with AP-5 (50 µM), as has been reported in other studies (Huang and Kandel 1998).

Next, we examined the effects of the NOS inhibitor 7-Nitroindazole (7-Ni; 30 µM), the sGC inhibitor LY83583 (5 µM), and the PKG inhibitor Rp-8-Br-PET-cGMPS (1 µM) on LTP at cortico-LA synapses.

Our 100-Hz protocol successfully induced LTP at cortical inputs to the LA that was significantly impaired by bath application of AP-5 (Fig. 4B). Control slices exhibited 130.77% potentiation, which differed significantly from baseline levels (t(7) = 3.31, P < 0.05). In contrast, slices perfused with AP-5 failed to exhibit LTP, with potentiation levels remaining at 109.53% (t(8) = 1.64). Further, control and AP-5-treated slices differed significantly from each other (t(15) = 1.91; P < 0.05; one-tailed).

In contrast to slices treated with AP-5, slices treated with 7-Ni, LY83583, or Rp-8-Br-PET-cGMPS exhibited intact LTP at cortical inputs (Fig. 4B–D). In the 7-Ni experiment, control slices potentiated to 130.77% (t(15) = 3.31, P < 0.05). Slices perfused with 7-Ni potentiated similarly to 129.51% (t(20) = 2.27, P < 0.05).
Further statistical analyses showed that the ACSF and 7-Ni-treated slices did not differ statistically in their amount of potentiation \((t_{17} = 0.07)\), showing no effect of the drug on cortical LTP. A similar finding was observed following bath application of the sGC inhibitor LY83583 (Fig. 4C). The control slices potentiated to 120.46 ± 9.50%, which differed significantly from baseline levels \((t_{10} = 2.17; P < 0.05; \text{one-tailed})\). Similarly, LY83583-treated slices exhibited 120.88 ± 10.32% potentiation, which differed significantly from baseline levels \((t_{11} = 2.03, P < 0.05; \text{one-tailed})\), but not from ACSF-treated controls \((t_{21} = 0.02)\). Finally, bath application of the PKG inhibitor Rp-8-Br-PET-cGMPS also failed to impair LTP at cortical inputs to the LA (Fig. 4D). Control slices showed 130.78 ± 9.40% potentiation, which was significantly different from baseline \((t_{7} = 3.31, P < 0.05)\). Inhibitor-treated slices behaved similarly: They showed 137.07 ± 18.97% potentiation, which was significantly different from baseline \((t_{8} = 2.02, P < 0.05; \text{one-tailed})\) and did not differ from control slices in their levels of potentiation \((t_{15} = 0.29)\).

Importantly, none of the drugs used in this experiment were found to have effects on routine transmission at cortical inputs to the LA. Bath application of AP-5 (Fig. 4B, inset), 7-Ni (Fig. 4B, inset), LY83583 (Fig. 4C, inset), or Rp-8-Br-PET-cGMPS (Fig. 4D, inset) all failed to affect the baseline amplitude of evoked responses (AP-5: \(t_{6} = 0.49\); 7-Ni: \(t_{10} = 0.63\); LY83583: \(t_{11} = 0.47\); Rp-8-Br-PET-cGMPS: \(t_{8} = 0.88\), respectively).

Collectively, these findings suggest that LTP at cortical inputs to the LA is not impaired by inhibitors of the NO-cGMP-PKG signaling pathway. These findings replicate and extend those of a previous study (Watanabe et al. 1995) and suggest that synaptic plasticity at thalamic and cortical inputs to the LA may be subserved, in part, by distinct biochemical mechanisms.

**Activation of PKG in the lateral amygdala enhances fear memory consolidation and synaptic plasticity at thalamo-LA synapses**

Our previous experiments relied exclusively on pharmacological inhibitors of the NO-cGMP-PKG signaling pathway. To further examine the role of PKG in fear memory formation, in this series of experiments we examined the effect of a pharmacological activator of PKG on fear memory consolidation and LTP at thalamo-LA synapses. In behavioral experiments, we gave rats intra-LA infu-
sion of vehicle (0.5 µL 0.9% NaCl) or of different doses of the PKG activator 8-Br-cGMP (1.0 or 10.0 µg/side; 0.5 µL) prior to auditory conditioning, and examined retention at 1, 3, 6, and 24 h after training (Fig. 5A). In slice electrophysiology experiments, we bath-applied 8-Br-cGMP (1 µM) or the sGC activator YC-1 (1 µM) to amygdala slices prior to LTP induction. In our behavioral experiments, we used a slightly weaker training protocol consisting of two tone-shock pairings, so that enhancements in fear memory could be readily observed. Similarly, in our LTP experiments, we used a protocol that does not by itself reliably induce long-lasting LTP (three 100-Hz trains, separated by 1 min, at test stimulation intensity; see Materials and Methods for details).

**Behavioral experiments**

Rats infused with either dose of 8-Br-cGMP exhibited intact post-shock freezing during training that did not significantly differ from that of vehicle-infused controls (Fig. 5B). The ANOVA for post-shock freezing scores showed only a significant effect of trial ($F_{(2,62)} = 70.46, P < 0.001$); the effect of drug ($F_{(2,31)} = 1.45$) and the drug by trial interaction ($F_{(4,62)} = 0.56$) were not significant. Similarly, 8-Br-cGMP-infused rats tested for auditory fear memory 1 h following conditioning were found to have intact short-term memory (Fig. 5C). The ANOVA for fear memory at 1 h showed only a significant effect for trial ($F_{(2,62)} = 4.64, P < 0.05$). The effect for drug ($F_{(2,31)} = 1.70$) and the drug by trial interaction ($F_{(4,62)} = 1.14$) were not significant. Similarly, at 3 h, each group exhibited equivalent retention (Fig. 5D). The ANOVA for the 3-h memory test revealed no significant effect of drug condition ($F_{(2,31)} = 1.83$), trial ($F_{(2,62)} = 0.73$), or drug-by-trial interaction ($F_{(4,62)} = 2.41$).

At 6 h, however, a difference began to emerge in the group treated with the highest dose of the PKG activator (Fig. 5E). The

**Figure 5.** Activation of PKG in the LA enhances auditory fear memory consolidation. (A) Schematic of the behavioral protocol. Rats were given intra-LA infusion of the vehicle or a high (10 µg) or low (1 µg) dose of 8-Br-cGMP. Sixty minutes later they were trained with two tone-shock pairings, then tested for retention of auditory fear conditioning at 1, 3, 6, and 24 h following conditioning. (B) Mean (± SEM) post-shock freezing between conditioning trials in rats given intra-LA infusions of 0.15M NaCl (vehicle; $n = 11$), 1 µg 8-Br-cGMP ($n = 12$), or 10 µg 8-Br-cGMP ($n = 11$). (C) Mean (± SEM) auditory fear memory assessed at 1 h following conditioning. (D) Mean (± SEM) auditory fear memory assessed at 3 h following conditioning. (E) Mean (± SEM) auditory fear memory assessed at 6 h following conditioning. (F) Mean (± SEM) auditory fear memory assessed at 24 h following conditioning. (G) Percentage of STM in each group. Each rat’s 24-h memory score is expressed as a percentage of its 1-h memory score. (H) Percentage of STM in each group. Each rat’s 24-h memory score is expressed as a percentage of its 1-h memory score. (I) Histological verification of cannula placements for rats infused with 10 µg 8-Br-cGMP (gray circles), 1 µg 8-Br-cGMP (black circles), or 0.15 M NaCl vehicle (black squares). Panels adapted from Paxinos and Watson (1997). (J) Mean (± SEM) percentage field potential amplitude (relative to baseline) in slices treated with vehicle ($n = 6$; black circles) or 1 µM 8-Br-cGMP ($n = 7$; gray circles). Traces from an individual experiment before and 50 min following tetanic stimulation and transmission following 30 min of bath application of drug are shown in the inset. Scale, 0.2 mV by 10 msec. (*) $P < 0.05$ relative to vehicle.
ANOVA for the 6-h memory test showed a significant effect of drug condition \( F_{2,31} = 3.76, P < 0.05 \). The effect of trial \( F_{2,62} = 3.04 \) and the drug by trial interaction \( F_{4,62} = 2.01 \) were not significant. This difference became even more pronounced at 24 h after training (Fig. 5F), with the ANOVA revealing a significant effect of drug condition \( F_{2,31} = 4.17, P < 0.03 \) and of trial \( F_{2,62} = 4.27, P < 0.02 \). The drug by trial interaction \( F_{4,62} = 1.85 \) was not significant. Duncan’s post-hoc t-tests revealed that both the high- and low-dose drug groups differed significantly from the vehicle group on each trial of the LTM test \( (P < 0.05) \). Similarly, examination of the long-term memory (24 h) as a function of short-term memory (1 h) revealed a significant group difference based on drug condition \( F_{2,31} = 3.83, P < 0.04 \), with Duncan’s post-hoc t-tests revealing a significant difference between the vehicle control and both the high- and low-dose conditions \( (P < 0.03 \) for both) (Fig. 5G).

Histological verification of the cannula placements for rats infused with 8-Br-cGMP is presented in Figure 5H. Cannula tips were observed to lie throughout the LA at various rostro-caudal levels. Only rats with cannula tips at or within the boundaries of the LA or the adjacent basal nucleus were included in the data analysis.

**Slice electrophysiology**

We next examined the effects of PKG activation on synaptic plasticity at thalamic inputs to the LA. For this experiment, we used a low concentration of 8-Br-cGMP (1 µM) that is highly specific to cGMP, but has little affinity for other kinases such as PKA (Lu et al. 1999). Bath application of 8-Br-cGMP was found to enhance LTP at thalamic inputs to the LA compared with slices treated with ACSF only (Fig. 5I). As expected, our control (ACSF)-treated slices failed to exhibit potentiation using the weaker LTP induction protocol. Control slices showed 98.06 ± 4.03% potentiation, which did not differ significantly from baseline \( (t_{60} = 0.23) \). In contrast, slices treated with 8-Br-cGMP exhibited enhanced LTP, potentiating to 114 ± 6.33%, which differed significantly from both baseline \( (t_{60} = 2.09, P < 0.05 \) one-tailed) and the level of LTP in control slices \( (t_{11} = 1.99, P < 0.05 \) one-tailed).

To further explore the role of PKG in amygdala LTP, we next examined the effect of YC-1, an sGC activator, on LTP at thalamo-LA synapses. Similar to the findings with the PKG activator, YC-1 was found to enhance thalamo-LA LTP relative to slices treated with ACSF (Fig. 6A). As before, the control slices failed to exhibit LTP (96.47 ± 5.04%), which did not differ significantly from baseline \( (t_{60} = 0.10) \). In contrast, the YC-1-treated slices potentiated to 124.83 ± 3.84%, which differed significantly from baseline \( (t_{60} = 2.62, P < 0.05) \). The YC-1-treated slices were also found to exhibit significantly higher levels of LTP than control slices \( (t_{12} = 2.42, P < 0.05) \). Thus, activation of both PKG and sGC enhanced LTP at thalamic inputs to the LA.

To verify whether the sGC activator was, in fact, enhancing LTP by activating PKG, we next examined the effects of bath application of a drug combination of YC-1 (sGC activator) and Rp-8-Br-PET-cGMP (PKG inhibitor) on LTP at thalamic inputs. The sGC activator YC-1, which was found to enhance LTP in slices (Fig. 6A), was perfused in conjunc-
tion with the PKG inhibitor Rp-8-Br-PET-cGMPS, previously shown to inhibit LTP in slices (Fig 3B), to determine whether the LTP enhancement induced by YC-1 could be blocked by simultaneously inhibiting PKG (Fig 6B). Indeed, this hypothesis was supported. The slices perfused with YC-1 alone exhibited 124.10 ± 8.46% potentiation, which differed significantly from baseline (t(12) = 2.85, P < 0.05). In contrast, the slices perfused concurrently with YC-1 and Rp-8-Br-PET-cGMPS exhibited 93.63 ± 7.25% potentiation, which did not differ significantly from baseline (t(20) = 0.70), but did differ significantly from the YC-1-treated group (t(10) = 2.09, P < 0.05; one-tailed).

Importantly, none of the drugs used in these experiments, either alone or in combination, were found to have effects on routine transmission at thalamo-LA synapses. Bath application of 8-Br-cGMP or YC-1 alone (Figs. 51, 6A, insets) failed to affect the baseline amplitude of evoked responses (8-Br-cGMP: t(6) = 0.16; YC-1: t(6) = 0.42). This pattern of findings indicates that it was the combination of weak tetanus and drug that promoted LTP at thalamo-LA synapses, not the perfusion of the drug alone. Further, co-application of both YC-1 and Rp-8-Br-PET-cGMPS also failed to affect baseline evoked responses (t(4) = 0.58; Fig 6B, inset), indicating that the reversal of YC-1 induced LTP in the LA was not due to impaired synaptic transmission as a result of perfusion of two different drugs onto the slice.

These findings, together with those of our experiments examining the effects of inhibition of sGC-cGMP-PKG signaling (above), suggest a crucial role for PKG and its upstream regulators in fear memory consolidation and LTP at thalamic inputs to the LA.

The NO-cGMP-PKG signaling pathway promotes synaptic plasticity and fear memory consolidation via activation of ERK/MAPK

Our experiments collectively suggest that signaling via NO-cGMP-PKG regulates fear memory consolidation and associated synaptic plasticity in the LA. In this final series of experiments, we wanted to explore a potential mechanism by which LTP and fear memory consolidation might be promoted by NO-cGMP-PKG signaling in the LA. A recent study has suggested that ERK/MAPK is a critical downstream mediator of NO signaling in the hippocampus (Chien et al. 2003). In that study, YC-1-induced enhancement of LTP in hippocampal area CA1 was shown to be reversed by the MEK inhibitor PD098059. Further, LTP induced by co-perfusion of YC-1 and the NO donor Na-nitroprusside led to significant activation of both ERK and the transcription factor CREB in CA1 neurons (Chien et al. 2003). These findings suggest that the NO-cGMP-PKG signaling pathway might promote synaptic plasticity and memory consolidation, in part, by activation of the MEK-ERK-CREB signaling cascade, a signaling cascade that has been widely implicated in memory consolidation, including fear memory consolidation (Atkins et al. 1998; Schafe et al. 2000; Josselyn et al. 2001). To evaluate this possibility in our system, we first used slice-recording methods to determine whether YC-1-induced enhancement of LTP at thalamic inputs to the LA could be reversed by concurrent administration of the MEK inhibitor U0126 (5 µM). Next, we examined whether ERK activation following fear conditioning is impaired, or enhanced, respectively, under the influence of the PKG inhibitor Rp-8-Br-PET-cGMPS (1 µg) or the PKG activator 8-Br-cGMP (10 µg).
ERK1 vs. ERK2; $F_{(1,36)} = 0.014, P > 0.05$), and a nonsignificant drug by kinase interaction ($F_{(1,36)} = 0.014, P > 0.05$). Again, this increase is not accounted for by differences in total ERK. Total ERK/MAPK levels were not significantly changed from vehicle levels following infusion of 8-Br-cGMP (Fig. 7F). The ANOVA revealed a nonsignificant effect for drug ($F_{(1,36)} = 0.011, P > 0.05$), a nonsignificant effect for kinase ($F_{(1,36)} = 0.006, P > 0.05$), and a nonsignificant drug by kinase interaction ($F_{(1,36)} = 0.006, P > 0.05$).

Together with our LTP experiment, these results suggest that the NO-cGMP-PKG signaling pathway affects fear memory consolidation and synaptic plasticity in the LA, in part, by promoting the activation of ERK/MAPK.

**Discussion**

We have recently shown that NO signaling in the LA is critical for synaptic plasticity and fear memory consolidation (Schafe et al. 2005a). The current study sought to further examine the NO signaling pathway in fear memory formation by examining downstream targets of NO signaling in the LA, including the role of PKG and its immediate upstream regulators. Collectively, our findings suggest that signaling via PKG regulates both fear memory consolidation and synaptic plasticity in the LA, providing further evidence that the NO-cGMP-PKG signaling pathway is critical for fear memory formation.

**The NO-cGMP-PKG signaling pathway is required for fear memory formation**

In our behavioral experiments, we examined the role of PKG signaling specifically in auditory fear conditioning and in the LA. We found that intra-LA infusion of the PKG inhibitor Rp-8-Br-PET-cGMPS impaired fear memory formation. Specifically, LTM was impaired, while STM, measured within hours of training, was intact. In contrast, infusion of the PKG activator 8-Br-cGMP enhanced LTM, but similarly had no effect on STM. The fact that fear acquisition and STM formation was left intact after manipulation of PKG signaling rules out possible nonspecific explanations of the drug effect, including the possibility that either drug influenced fear acquisition by impairing (or enhancing) sensory and/or performance factors, including the ability of the LA to process tone and shock information.

Intact acquisition and STM formation also rules out potential effects of manipulation of the NO signaling pathway in the LA on motivational factors that might influence fear conditioning. A previous study has shown that intra-LA infusion of a NOS inhibitor produces an anxiogenic state in rats as measured by the
elevated plus maze (Monzón et al. 2001). Such an effect might therefore also be predicted following infusion of an inhibitor of PKG. Given the fact that anxiogenic drugs, including dopamine receptor agonists (Sullivan et al. 2003), adrenergic agonists (Davis et al. 1979), and acutely administered SSRIs (Burghardt et al. 2004), are all known to facilitate, rather than impair fear conditioning, our results are not consistent with this finding. Further, the Monzón et al. (2001) findings would suggest that activation of PKG in the LA should be anxiolytic, a conclusion that our data are also clearly not consistent with. Rather, our findings, when considered together with our recent findings that showed impaired fear memory consolidation following infusion of an inhibitor of NOS or of a membrane-impermeable scavenger of NO (Schafe et al. 2005a), provide strong evidence that NO signaling is required for fear memory consolidation and associated synaptic plasticity in the amygdala.

The NO-cGMP-PKG signaling pathway is required for synaptic plasticity in the LA, but only at thalamic inputs

In our neurophysiology experiments, we found that pharmacological blockade or activation of the cGMP-PKG signaling pathway impaired or enhanced LTP at thalamic inputs to the LA, respectively. These findings are consistent with those of our recent findings, which showed that LTP occludes paired pulse facilitation at thalamic inputs to the LA, and that bath application of an inhibitor of NOS or a scavenger of NO impairs thalamo-LA LTP (Schafe et al. 2005a). Further, the fact that LTP was impaired whether Rp-8-Br-PET-cGMP was present in the bath or in the recording pipette suggests that the NO-cGMP-PKG signaling pathway acts, at least in part, at postsynaptic sites to promote facilitation at thalamic inputs to the LA, and that bath application of forskolin, a PKA activator, in the presence of antagonists of postsynaptic NMDAR activator, in the presence of antagonists of postsynaptic NMDAR type voltage-gated calcium channels or inhibitors of protein synthesis, PKA, ERK/MAPK activity or NO signaling begins to impair LTP immediately after induction (Huang et al. 2000; Schafe et al. 2000, 2005a; Bauer et al. 2002), whereas intra-amygdala infusion of the same compounds in behavioral experiments produces memory deficits that emerge between 6 and 24 h after conditioning (Schafe and LeDoux 2000; Schafe et al. 2005a; Bauer et al. 2002). Any number of factors might account for the temporal discrepancy between LTP and memory formation. For example, in vitro LTP studies use artificial patterns of electrical stimulation to induce LTP, which may be very different from natural activity patterns that occur in the LA of behaving animals during CS-US pairing. Further, neurons undergo significant trauma during preparation of brain slices for in vitro experiments, and they are disconnected from many of the modulatory inputs that are normally present in vivo. These factors may be responsible for quantitative differences in the time course of the effects of drugs on protein synthesis-dependent LTP and LTM formation, even though both phenomena involve qualitatively similar molecular signaling pathways. It is clear that a complete understanding of how synaptic plasticity in the LA and fear conditioning are related will require attention to the relationship between naturally occurring plasticity in the LA and fear memory formation (Schafe et al. 2005b).

The NO-cGMP-PKG signaling pathway acts via the ERK/MAPK signaling cascade

The finding of the present study are the first to point to a potential mechanism by which the NO signaling pathway affects fear memory consolidation and synaptic plasticity in the LA. Co-application of the MEK inhibitor U0126 reversed the LTP-enhancing effects of the sGC inhibitor YC-1 in LA slices, indicating that YC-1 enhancement of synaptic plasticity in the LA is dependent on ERK activation. In behavioral experiments, intra-LA infusion of the PKG activator 8-Br-cGMP enhanced training-induced ERK activation in LA homogenates, while infusion of the PKG inhibitor Rp-8-Br-PET-cGMP resulted in impaired training-induced ERK activation in the LA. Together, these findings suggest that the NO-cGMP-PKG signaling pathway acts to promote fear memory formation and synaptic plasticity in the LA, in part by activation of ERK in LA neurons. This pattern of findings is in agreement with previous studies that have suggested that one of the mechanisms by which NO exerts its effects on synaptic plasticity and memory is by engaging parallel activation of “classical” signaling cascades, including ERK/MAPK and the transcription factor CREB (Lu et al. 1999; Chien et al. 2003). It has long been known that ERK is a critical signaling cascade in fear conditioning (Atkins et al. 1998; Schafe et al. 2000), but the critical upstream mediators of ERK signaling in the LA have not been identified. The findings of the present study provide some of the first support that NO and its downstream effectors may be one of...
these critical mediators, although additional experiments will be required to explore how PKG and ERK might interact in the signaling cascade. While the mechanism by which NO signaling leads to ERK activation in the LA during fear learning is presently unknown, previous studies have suggested that PKG or its downstream substrates can activate Raf-1, an upstream regulator of ERK1/2 (Hood and Granger 1998), or inhibit protein phosphatase-1 (Hall et al. 1998), which may indirectly regulate ERK1/2.

Importantly, while the findings of the present study clearly suggest that activation of ERK-mediated signaling in LA neurons is one mechanism by which the NO-cGMP-PKG signaling pathway promotes fear memory consolidation, they do not rule out the possibility that NO signaling in the LA also plays a role in presynaptic aspects of plasticity in the LA. Our Western blotting experiments (Fig. 7), for example, indicate that PKG signaling regulates ERK activation in LA homogenates, but the possibility remains that all or part of this regulation might be localized to presynaptic terminals in the LA. Further, while previous studies from our laboratory have clearly implicated the importance of ERK activation in the LA in fear memory consolidation (Schafe et al. 2000), more recent findings have also implicated the importance of ERK-mediated signaling in the auditory thalamus (Apergis-Schoute et al. 2005). In those experiments, intra-thalamic infusion of the MEK inhibitor U0126 or the mRNA synthesis inhibitor DRB impaired fear memory consolidation, while infusion of the protein synthesis inhibitor anisomycin did not (Apergis-Schoute et al. 2005). These findings suggest that while ERK-driven transcription in auditory thalamic neurons is critical for fear memory consolidation, it is not itself a site of fear memory storage. Importantly, intra-thalamic infusion of U0126 was also observed to impair LTP at thalamic inputs to the LA, suggesting that the role of ERK-dependent signaling in the auditory thalamus is to promote presynaptic aspects of plasticity at thalamo-LA synapses (Apergis-Schoute et al. 2005). At present, it remains unclear how ERK-driven transcription in the thalamus is engaged by fear conditioning. However, it may well be possible that NO signaling in the LA engages, in parallel, ERK activation in both LA and the auditory thalamus during the process of fear memory consolidation. In this manner, NO may serve as the link between intracellular signaling in the LA and that in its afferent targets during the process of fear memory consolidation. Further experiments will be necessary to examine this possibility.

In summary, the results of the present study clearly suggest that signaling via PKG regulates long-term regulation and fear memory consolidation in the LA. These findings provide further evidence for a role for the NO-cGMP-PKG signaling pathway in fear memory formation and associated synaptic plasticity in the LA and make an additional contribution toward understanding the cellular and molecular processes underly ing emotional memory formation in the amygdala.

Materials and Methods

Subjects

Adult male Sprague-Dawley rats (Harlan), weighing 300–325 g, were housed individually in plastic cages and maintained on a 12:12 h light/dark cycle. Food and water were provided ad libitum throughout the experiment.

Drugs

In the behavioral experiments, we used the PKG inhibitor guanosine 3',5'-cyclic monophosphorothioate, β-Phenyl-1, N³-etheno-8-bromo-, Rp-Isomer, sodium salt (Rp-8-Br-PET-cGMP; Calbiochem, Cat. No. 370679) and the PKG activator guanosine 3',5'-cyclic monophosphate, 8-Bromo-, sodium salt (8-Br-cGMP; Calbiochem, Cat. no. 203820). The drugs were dissolved in distilled water in a stock concentration of either 2 µg/µL (Rp-8-Br-PET-cGMP) or 20 µg/µL (8-Br-cGMP).

In the electrophysiological experiments, we used the PKG drugs outlined above in addition to the sGC activator 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole (YC-1; Calbiochem Cat. No. 688100), the MEK inhibitor U0126 (Promega, Cat. No. V1121), the NOS inhibitor 7-nitroindazole (7-Ni; Calbiochem Cat. No. 483400), the sGC inhibitor 6-Anilino-5,8-quinalinol inequinoine (LY 83583; Cat. No. 440205), and the NMDA receptor antagonist D-(-)-2-Amino-5-phosphonopentanoic Acid (AP-5; Calbiochem Cat. No.165304). All drugs, with the exception of Rp-8-Br-PET-cGMP, were diluted in 100% DMSO into stock concentrations of 1 mM (8-Br-cGMP and YC-1), 5 mM (LY 83583), 10 mM (U0126), 30 mM (7-Ni), or 40 mM (AP-5). The Rp-8-Br-PET-cGMP, because it is water soluble, was diluted in distilled water in a stock concentration of 1 mM. For use in experiments, all drugs were further diluted in ACSF to a final concentration of 1000-fold less than the stock concentration.

Surgical procedures

Under a mixture of Ketamine (100 mg/kg) and Xylazine (6.0 mg/kg) anesthesia, rats were implanted bilaterally with 23-gauge stainless-steel guide cannulae aimed at the LA. The coordinates for the LA were: −3.2 mm, ±5.0 mm, −8.0 mm relative to Bregma. The guide cannulas were fixed to screws in the skull using a mixture of acrylic and dental cement, and a 26-gauge dummy cannula was inserted into each guide cannula to prevent clogging. Rats were given Buprenex (0.2 mg/kg) as an analgesic and given at least 5 d to recover prior to experimental procedures. All procedures were conducted in accordance with the National Institutes of Health “Guide for the Care and Use of Experimental Animals” and were approved by the Yale University Animal Care and Use Committee.

Behavioral procedures

On the day prior to conditioning, rats were habituated to the conditioning chamber and to dummy cannula removal for a minimum of 10 min. The following day, rats were given an intra-LA infusion of either 0.5 µl 0.9% NaCl (vehicle), Rp-8-Br-PET-cGMP (0.1 or 1.0 µg/side in 0.5 µl), or 8-Br-cGMP (1.0 or 10 µg/side in 0.5 µl). All infusions were given at a rate of 0.25 µL/min. Injectors remained in the cannulas for 1 min after drug infusion to allow diffusion of the drug from the tip. Sixty minutes following drug infusion, rats infused with Rp-8-Br-PET-cGMPs (and their respective Vehicle controls) were trained with three conditioning trials consisting of a 20-sec, 5-kHz, 75-dB tone that co-terminated with a 1.0-sec, 0.5-mA foot shock (ITI = 120 sec). Rats infused with 8-Br-cGMP (and their respective controls) were trained as above, but with only two training trials to maximize our ability to observe enhancements in fear acquisition and/or retention.

Testing for conditioned fear to the tone occurred at 1, 3, 6, and 24 h following training. For each test, rats were placed in a distinctive environment that was dark and consisted of a flat black plastic floor that had been washed with a peppermint-scented soap. For the 1-, 3-, and 6-h retention tests, rats were exposed to three conditioned stimulus (CS) tones (5 kHz, 75 dB, 20 sec). For the 24 h test, rats were exposed to 10 CS tones for the Rp-8-Br-PET-cGMPs experiment and to three tones for the 8-Br-cGMP experiment. For each tone test, we measured the rats’ freezing behavior, defined as a lack of all movement, with the exception of that required for respiration, and expressed this measure as a percentage of the total CS presentation time. Freezing was calculated from activity counts measured automatically during each CS presentation by Coulbourn Instruments Activity Monitors (Model # H10-24A) mounted at the top of each of the behavioral chambers. For each memory test, freezing scores for each trial were averaged together as a single score for each rat. All data were analyzed with Analysis of Variance (ANOVA) and Duncan’s post-hoc t-tests. For behavioral experiments involving multiple trial comparisons (Figs. 1, 2, 4), repeated measures ANOVA was used. Differences were considered significant if P <0.05.
At the end of the behavioral experiment, rats were sacrificed by an overdose of chloral hydrate (600 mg/kg) and perfused with 0.9% saline followed by 10% buffered formalin. Nissl staining and light microscopy were used to verify the location of the cannula tips within the amygdala.

Slice electrophysiology
Male Sprague-Dawley rats (3-5 wk old) were deeply anesthetized with ketamine, and the brain was rapidly removed and transferred to ice-cold ACSF containing (in millimolars): 115 NaCl, 3.3 KCl, 1 MgSO4, 2 CaCl2, 25.5 NaHCO3, 1.2 Na2HPO4, and 10 glucose, equilibrated with 95% O2/5% CO2. Coronal slices (400-µm thick) containing the amygdala were cut and recovered in a holding chamber at 32°C–34°C for 30 min and were then allowed to return to room temperature for at least another 30 min before recording. An upright microscope equipped with infrared differential interference contrast optics (IR-DIC) was used to perform whole-cell patch or field recordings under visual guidance. For field recording experiments, glass-recording electrodes were filled with ACSF. For whole-cell experiments, electrodes were filled (in millimolars): 130 K-Gluconate, 0.6 EGTA, 2 MgCl2, 5 KCl, 10 HEPES, 0.3 Na2GTP (pH 7.3, 290–300 mOsm). The electrodes typically had resistances of 4–8 MΩ. For some experiments, we dissolved the PKG inhibitor Rp-8-Br-PET-cGMPS (250 μM) in the internal solution. pH (7.3) and osmolarity (290–300 mOsm) were rechecked prior to using the drug in slice-recording experiments.

Stimuli (150-µsec duration) were delivered through bipolar stainless steel electrodes. For “thalamic” recording experiments, stimulation electrodes were placed in the ventral striatum, just medial to the LA. This stimulating protocol activates fibers that originate, at least in part, in the auditory thalamus (Weisskopf et al. 1999). For “cortical” recording experiments, stimulation electrodes were placed in the external capsule, just dorsal to the LA. This stimulating protocol activates fibers that originate, at least in part, in the auditory cortex (Chapman et al. 1990). The stimulation was kept at a minimum and adjusted for each cell or slice to produce a reliable EPSP or field-evoked response that was ~50% of the maximal response. Baseline responses were monitored at 0.06 Hz. Following stabilization of baseline responses, one of three different LTP-induction protocols was used. For whole-cell recording experiments, LTP was induced by delivering trains of stimuli at 30 Hz given twice at a 20-sec interval. This is a type of LTP induction protocol that, in the LA, is known to be NMDAR dependent (Bauer et al. 2002). For field recording experiments, we used a 100-Hz tetanus given three times at 1-min intervals at test intensity (weak protocol), or a 100-Hz tetanus given three times at 1-min intervals at 50% higher stimulation intensity (strong protocol). In our hands, this latter 100 Hz protocol produces a reliable LTP that lasts for at least 1 h, whereas the weaker 100 Hz protocol declines to baseline within ~30 min. Recordings were made at baseline test intensity for an additional hour after LTP induction in field-recording experiments and for an additional 30 min in whole-cell experiments.

Picrotoxin (50 µM) was included in the bath in all experiments to block fast GABAergic transmission. Each slice was recorded from only once, and thus, control and drug conditions were always from different slices. Typically, both vehicle and drug conditions were run from separate slices from the same animal on the same day. In control experiments, slices were perfused with ACSF/50 µM picrotoxin vehicle alone.

Data were acquired using Slice software (http://www.cns.nyu.edu/~sanes/slice_software/) written for Igor (NIH DC00540). EPSPs and field potentials were extracted from Igor and analyzed using Spike 2 software. In all experiments, the initial slope of the EPSP or amplitude of the negative-going field potential was measured, and LTP for each time point was expressed as a percentage of the pre-induction baseline. For analyses, measurements of evoked responses during the last 10 min of the recording session were compared with the last 5 min of the baseline period using Student’s t-tests.

Western blotting
In Western blotting experiments, rats were cannulated as described above. Rats were habituated to handling, conditioning chambers, and dummy cannula removal for 2 d prior to training. On the training day, animals were given an intra-LA infusion of either ACSF (vehicle, prepared as described under slice electrophysiology procedures), the PKG inhibitor Rp-8-Br-PET-cGMPS (1 μg/side in 0.5 μL; 0.25 μL/min), or the PKG activator 8-Br-cGMP (10 μg/side in 0.5 μL; 0.25 μL/min). Injectors remained in the cannulas for 1 min after drug infusion to allow diffusion of the drug from the tip. Sixty minutes following drug infusion, rats were trained with three or two conditioning trials, respectively, consisting of a 20-sec, 5-kHz, 75-db tone that co-terminated with a 1.0-sec, 0.5-mA foot shock (ITI = 120 sec). One hour following training, animals were sacrificed using an overdose of chloral hydrate (600 mg/kg) and decapitated. Brains were frozen and stored at −80°C until processed. Punches containing the LA were obtained with a 1-mm punch tool (Fine Science Tools) from 400-µm-thick sections taken on a sliding freezing microtome. Punches were manually dounced in 50 µL of ice-cold hypotonic lysis buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 2.5 mM sodium pyrophosphate, 1 mM phenylmethylsulfonyl fluoride, 1 mM β-glycerophosphate, 1% Igepal CA-630, 1% protease inhibitor cocktail [Sigma], and 1% sodium orthovanadate). Protein concentrations were assessed and normalized across homogenates using a Bradford assay. Sample buffer was immediately added to the homogenates, and the samples were boiled for 4 min. Homogenates were electrophoresed on 10% Tris-HCl gels and blotted to Immobilon-P (Millipore). Western blots were blocked in 5% milk and then incubated with an anti-phospho-MAPK (1:1000; Cell Signaling) or an anti-total MAPK antibody (1:1000; Cell Signaling). Blots were then incubated with anti-rabbit conjugated to horseradish peroxidase and developed using enhanced chemiluminescence (Pierce). Optical densities of the bands were analyzed using NIH Image software. To assess for changes in the activation of ERK/MAPK, phosphorylated kinase levels were normalized to total ERK levels. Activated ERK levels in drug-infused rats were then expressed as a percentage of those in vehicle-infused rats. To confirm that total ERK levels remained constant across infusions, blots were blocked in 5% BSA in TTBS and reincubated in GAPDH antibody (1:5000; Abcam). Following incubation with anti-mouse conjugated to horseradish peroxidase, blots were developed identically to those processed for phospho-ERK and total ERK. Total ERK levels were then normalized to GAPDH levels for analysis.

Acknowledgments
This research was supported by the National Science Foundation (NSF 0444632 to G.E.S.), the National Institutes of Health (MH 073949 to G.E.S.), and by Yale University. K.T.O. is supported by a National Science Foundation Graduate Research Fellowship. We thank Grace Young and Kunmi Sobowale for technical assistance.

References


Received June 19, 2008; accepted in revised form August 11, 2008.
The NO-cGMP-PKG signaling pathway regulates synaptic plasticity and fear memory consolidation in the lateral amygdala via activation of ERK/MAP kinase


*Learn. Mem.* 2008 15: 792-805
Access the most recent version at doi:10.1101/lm.1114808

**References**

This article cites 46 articles, 20 of which can be accessed free at: [http://learnmem.cshlp.org/content/15/10/792.full.html#ref-list-1](http://learnmem.cshlp.org/content/15/10/792.full.html#ref-list-1)

**Email Alerting Service**

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](http://learnmem.cshlp.org/subscriptions).

To subscribe to *Learning & Memory* go to: [http://learnmem.cshlp.org/subscriptions](http://learnmem.cshlp.org/subscriptions)